- Scientific principles underlying the use of CAR T-cells
- Current best practices and emerging strategies in using CAR T-cell therapies for patients with
- Identifying and understanding the challenges that may hinder community oncologists’ use of and referral for CAR T-cell therapy
- Best practices in identifying and managing CAR T-cell–mediated toxicities
Date / Time
Michael Bishop, MD
Professor of Medicine
Director, Hematopoietic Stem Cell Transplantation Program
University of Chicago
Jae Park, MD
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York
Caron A. Jacobson, MD
Medical Director, Immune Effector Cell Therapy Program
Assistant Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate current and emerging CAR T-cell therapies into the treatment of patients with leukemia, lymphoma, or multiple myeloma.
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with leukemia, lymphoma, and multiple myeloma.
Upon completion of this activity, participants should be able to:
- Integrate recent developments, clinical trial findings, and indications of recently approved and emerging CAR T-cell therapies into clinical practice to enhance clinical outcomes of patients with of leukemia, lymphoma, and multiple myeloma
- Determine best practices for timely referral and having proper channels of communication between community and academic centers to streamline the logistics of delivering therapy, including appropriate referrals to specialized centers and enrollment in clinical trials
- Discuss key education elements for CAR T-cell therapy including considerations for each stage of therapy and specific recommendations for care teams, patients, and caregivers
- Apply multidisciplinary interventions to identify and manage acute toxicities and ensure patient safety while receiving CAR T-cell therapy
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Live event Universal Activity Number -JA4008176-0000-21-014-L01-P
Webinar Universal Activity Number -JA4008176-0000-21-015-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.